Bromodomains: pockets with therapeutic potential.
Intense interest in the complex biology of the bromodomain (BRD) protein modules has fueled the development of novel small molecule inhibitors that target the acetyl-lysine (KAc) binding pocket of the BRD. BRD inhibition has revealed exciting opportunities for treating a variety of maladies such as cancer, inflammation, obesity, cardiovascular disease, and neurological disorders. With five BRD inhibitors already in clinical trials, the BRD field seems to be rising to success.